Skip To Main Content
Xue Hou on Muck Rack

Xue Hou

As seen in: Color Research & Application, Wiley Online Library, MDPI, SAGE Publishing, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, Royal Society of Chemistry, Canadian Journal of Infectious Diseases & Medical Microbiology, Dialnet - Universidad de La Rioja, Chemistry World and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xue

Contact Xue, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer : The HARMONi-A Randomized Clinical Trial

|
By HARMONi-A Study Investigators, Wenfeng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li, Qibin Song, Xiaobo Du, Yulan Sun, Wei Li, Longhua Sun, Zhiyu Wang, Kunning Yang, Yun Fan, Baogang Liu, Hongyun Zhao, Ying Hu, Li Jia, Shen Xu, Tienan Yi, Dongqing Lv, Haitao Lan, Mengxia Li, Wenhua Liang, Yongsheng Wang, Hui Yang, Yuming Jia, Yuan Chen, Meiqi Shi, Chunling Liu, Ming Zhou, Jianya Zhou, Xianling Liu, Ningning Zhou, Ming He, Xiaorong Dong, Hualin Chen, Yongxing Chen, Haichuan Su, Xiaoling Li, Zhihong Zhang, Ying Liu, Likun Chen, Xue Hou, Yu Zhang, Jun Guo, Ruiqiang Ma, Hong Lu, Di Wu, Weineng Feng, Jianan Huang, Yan Wang, Xia Song, Jiewen Peng, Laiyu Liu, Yubiao Guo, Mengying Xia, Dongmei Lu, Mingxiu Hu, Zhongmin Wang, Baiyong Li, Michelle Xia, Li Zhang, Junguo Lu
| JAMA: Journal of the American Medical Association Verified
Key Points Question Does adding ivonescimab to chemotherapy improve overall survival in patients with epidermal growth factor receptor (EGFR) gene variant non–small cell lung cancer after disease progression with EGFR tyrosine kinase inhibitor (TKI) therapy? Findings In this phase 3, randomized, double-blind trial, ivonescimab plus chemotherapy significantly improved overall survival (median, 16.8 vs 14.1 months) and the 30-month survival rate (29.1% vs 18.4%) compared with chemotherapy alone.
Open in Who Shared Issue with article?

Development and evaluation of a ropivacaine-loaded hydrogel for prolonged nerve blockade and local anesthesia

|
By Qunfei Zhang, Qihang Yang, Zhen Chen, Xue Hou
| SAGE Publishing
Abstract This study explored the in vitro characteristics of a ropivacaine-loaded hydrogel designed for sustained local anesthesia, using a gelatin matrix crosslinked with different concentrations of NHS-PEG-NHS. The hydrogel was comprehensively characterized through electron microscopy, rheology, biocompatibility testing, drug release and degradation analysis, and neurotoxicity assessment.
Open in Who Shared Issue with article?

Bioremediation Potential of Rhodococcus qingshengii PM1 in Sodium Selenite-Contaminated Soil and Its Impact on Microbial Community Assembly

|
By Mu Peng, Chongyang Hu, Xue Hou, Guangai Deng
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 13 licensed articles (14 Total)